we describe a dog with thymoma and concurrent renal amyloidosis. A 7-year-old castrated male Weimaraner was presented for progressive anorexia, lethargy, and tachypnea. The dog was diagnosed with azotemia, marked proteinuria, and a thymoma that was surgically removed.
In an attempt to differentiate between thymoma and thymic lymphoma, ultrasound-guided Tru-Cut biopsies of the mass were performed. On histopathology, the mass demonstrated diffuse necrosis with some lymphocytes. The presence of lymphocytes combined with the mass location made thymoma or thymic lymphoma likely diagnoses.
However, a conclusive diagnosis could not be made due to the necrosis. Bacterial culture of a biopsy specimen yielded no growth.
Varying arrhythmias were noted throughout hospitalization. The dog's underlying rhythm was normal sinus rhythm with right bundle branch block and a short PR interval suggestive of ventricular preexcitation through an accessory pathway. During anesthetic induction, this rhythm was initially misinterpreted as an accelerated idioventricular rhythm and treated with lidocaine. While recovering postoperatively, the dog experienced intermittent paroxysms of narrow-complex tachycardia suspected to be supraventricular tachycardia conducted through the atrioventricular node. Occasional ventricular premature complexes of varying morphology were also noted. Various treatments were instituted for the tachycardia including diltiazem, procainamide, esmolol, and lidocaine with variable response to procainamide and diltiazem in restoring a normal rate. An echocardiogram was performed to assess the dog's heart given the frequent bouts of supraventricular tachycardia. The study was difficult due to the mass compressing the heart, however, there was subjectively decreased systolic function and questionable spontaneous contrast seen in the left ventricle, suggestive of vascular stasis.
On the evening of day 6, the dog started to develop noticeable facial edema suspected to be due to the mass compressing the vena cava. Because previous less invasive methods were unsuccessful in obtaining a definitive diagnosis, the dog's owner elected to pursue removal of the cranial mediastinal mass. Presurgical serum biochemical analysis on day 6 showed a static azotemia and a mild increase in liver enzymes compared to the previous day. Presurgical coagulation panel revealed normal PT and aPTT with increased D-dimers (1081 ng/mL;
[RI], 0-400 ng/mL).
On day 7, a median sternotomy was performed and a 0.7 kg, 7.6 3 15.2 cm mass was removed from the dog's cranial mediastinum.
A thoracostomy tube and esophagostomy tube were placed at the time of surgery.
After surgery, the dog was supported with fluid therapy (intravenous administration of hypotonic and isotonic crystalloids), esophagostomy tube feedings, a continuous rate infusion of fentanyl, gastroprotectants (sucralfate, omeprazole), metoclopramide, and broad spectrum antibiotics (ampicillin and metronidazole). Benazepril (0.5 mg/kg q24h) and clopidogrel (2 mg/kg PO q24h) were commenced to address the proteinuria and associated thrombotic risk, respectively. Urine production was closely monitored with an indwelling urinary catheter and remained above 1 mL/kg/h. The azotemia remained relatively static (day 8 creatinine: 6.9 mg/dL; day 10 creatinine: 6.3 mg/dL). The facial edema originally improved, however, on the evening of day 9 (2 days after surgery) it returned and continued to progress. Due to suspicion of a thrombus, D-dimers were reassessed and had decreased (796 ng/mL).
At this time, given the dog's progressive facial edema and recurrent tachycardia, a thoracic ultrasound was performed to look for potential thrombi in the great vessels that could be contributing to the facial edema and any cardiac abnormalities that could be predisposing him to arrhythmias. A large thrombus was present in the left ventricle reported in up to 1%-2% of human patients and include glomerulonephritis or nephrotic syndrome. 6, 14 Amyloidosis is characterized by the extracellular deposition of insoluble, haphazardly arranged fibrillary proteins with a characteristic beta-sheet conformation at the molecular level. 7, 8 Amyloid deposition can be generalized or organ-specific. It is an uncommon disorder in dogs, but the kidney is the most common site of amyloid deposition. 9 Proteinuria, with or without nephrotic syndrome, is the most common sequela of renal amyloidosis in humans and dogs. 7, 8 In human patients, renal amyloidosis is characterized by the type of protein that makes the amyloid fibrils and include serum AA, light chain amyloid, and hereditary dysproteinemias. 7 AA amyloidosis is associated with chronic inflammatory processes (such as arthritis, infection, familial Mediterranean fever) and neoplasms that lead to increased serum AA production.
Light chain amyloidosis results from plasma cell dyscrasias or lymphomas that produce amyloidogenic light chains. 7, 10 In hereditary amyloidosis, a genetic mutation leads to generation of an amyloidogenic protein. Familial amyloidosis in the Chinese Shar-Pei and Abyssinian cat are due to serum AA but there might be a familial predisposition for increased synthesis. 8 Interestingly, intratumoral amyloid production by Renal amyloidosis in non-Shar-Pei dogs occurs in middle aged to older dogs with common presentations similar to that of the dog in this report of anorexia, vomiting, and lethargy. 8, 9 A history of comorbid disease, such as neoplasia or inflammation, is commonly present in dogs with renal amyloidosis. 8 It is likely these patients also have another predisposing factor, such as decreased ability to clear amyloid, as secondary amyloidosis is rare in patients with chronic inflammatory disease. 9 As seen in this dog, leukocytosis and hypoalbuminemia are the most common hematologic and biochemical abnormalities described in dogs with renal amyloidosis. 8 Dogs with renal amyloidosis also commonly demonstrate azotemia, hypercholesterolemia, isosthenuria, and a UPC > 2. 8 We believe this dog developed renal amyloidosis in conjunction with the thymoma. Unfortunately, there was no urinalysis performed before this illness, so we cannot confirm the proteinuria was new. However, the severity of the proteinuria, the new and rapidly progressive azotemia while in hospital, and the dramatic thrombotic sequelae support a recent decompensation. Furthermore, reported median survival times in dogs with renal amyloidosis is only 5 days. 8 Mass spectrometry confirmed that this dog's amyloidosis was AA.
While AA renal amyloidosis has been reported to develop secondary to many chronic inflammatory and neoplastic diseases in people and dogs, it has not been reported secondary to thymoma in either species. In this case, the thymoma had regions of tumoral inflammation, necrosis, and inflammation of its fibrous capsule, all of which may have led to serum AA generation and subsequent amyloidosis as seen with other cases of tumors with inflammation. 13 Several other paraneoplastic glomulerulopathies have also been reported secondary to thymoma in humans including minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis, rapidly progressive glomerulonephritis, and lupus nephritis. 6, 14 Autoreactive T cell clones escaping negative selection in the abnormal thymic tissue or suppression of regulatory T-cells controlling self-tolerance are likely integral in development of thymoma-associated autoimmune disease and may have contributed to serum AA production in this case. 6, 15 Minimal change disease, a glomerulopathy associated with nephrotic syndrome, was described in an older woman with recurrent thymoma. 16 Interestingly, when her thymoma was treated and her proteinuria decreased, her Th17/regulatory T cell ratio decreased. 16 We propose that a combination of thymoma associated and immune dysregulation and tumoral inflammation may have resulted in renal amyloid deposition in this dog. This dog was euthanized due the presence of a large ventricular thrombus, which likely occurred as a complication of nephrotic syndrome. This dog demonstrated all components of the tetrad of nephrotic syndrome including proteinuria, hypoalbuminemia, peripheral edema, and hypercholesterolemia. Nephrotic syndrome is reported in 10% of non-Shar-Pei dogs with renal amyloidosis 8 and 24% of human patients with renal amyloidosis. 7 Nephrotic syndrome has been associated with hypercoagulable states and a predisposition for thrombosis in dogs and humans. [17] [18] [19] In our dog, renal amyloidosis and protein losing nephropathy (PLN) may have led to a hypercoagulable state and thrombosis. Thromboemboli were found in up to 38% of dogs with renal amyloidosis with both arterial and venous locations with pulmonary arterial thrombi being the most common. 8, 20 The incidence of thromboembolic complications in people with nephrotic syndrome has been reported as high as 44% 21, 22 and a recent thromboelastography (TEG) study in dogs with PLN found 89% of dogs were hypercoagulable by TEG analysis. 23 Dogs with nephrotic syndrome are thought to be hypercoagulable due to urinary loss of antithrombin, hyperfibrinogenemia as a result of ongoing inflammation, and platelet hyperaggregability secondary to hypoalbuminemia. 24 High molecular weight clotting factors such as factor V and VIII are also increased in humans with PLN, likely due to increased synthesis disproportionate to urinary loss. 22 Hypovolemia leading to vascular stasis may also be a predisposing factor to thromboembolism in some PLN patients. 25 In most dogs with PLN, the UPC ratio, serum albumin concentration, and plasma antithrombin activity are not predictive of thromboembolic complications and do not predict TEG-based hypercoagulability. 19, 23, 25 The lack of ability to identify one marker that predicts hypercoagulablity in dogs with PLN suggests the predisposition is multifactorial. Unfortunately, in this dog, The mass spectrometry instrument used for amyloid identification was funded by an NIH shared instrumentation grant program (grant number S10 OD018056).
